Inovio Biomedical Corporation

Type: Public
On the web: http://www.inovio.com

Inovio Biomedical is electrifying patients with its therapies. The firm focuses on electroporation, an infusion therapy that uses electricity to open cell membranes to allow drugs or gene therapies to enter. The company is developing its MedPulser electroporation system to deliver chemotherapy to treat a variety of cancers without the debilitating side effects of traditional treatments. The firm is exploring the use of the electroporation system for gene therapy and DNA vaccines. The MedPulser SECTA system (for treating solid tumors) has been approved for use in Europe. Inovio Biomedical is looking for a partner to commercialize the system there.

Key numbers for fiscal year ending December, 2007:
Sales: $4.8M
One year growth: 38.6%
Net income: ($11.2)M

Officers:
Chairman: James L. Heppell
President, CEO, and Director: Avtar Dhillon
CFO: Peter D. Kies

Competitors:
Genentech
ImClone
Varian Medical Systems